Curaleaf First to Secure Registration for Standardized Cannabis Preparations in Spain

Rhea-AI Summary

Curaleaf (OTCQX: CURLF, TSX: CURA) announced that Spain's Agency of Medicines and Medical Devices (AEMPS) has formally approved the registration of two standardized cannabis preparations, THC-dominant and CBD-dominant, developed by its Spanish manufacturing subsidiary. These registrations enable supply to hospital pharmacies for use in magistral formulas under medical prescription.

According to Curaleaf, the products received registry numbers CAN-1 and CAN-2, making the company the first to register standardized cannabis preparations in Spain under Royal Decree 903/2025, which defines the national framework for medicinal use of standardized cannabis preparations. The milestone builds on Curaleaf's EU-GMP certified manufacturing and R&D facility in Alicante and Medalchemy SL's 2020 AEMPS license to process medicinal cannabis derivatives for commercial distribution.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Positive

• First standardized cannabis registrations in Spain with CAN-1 and CAN-2 under Royal Decree 903/2025
• Regulatory pathway cleared for Curaleaf to supply standardized THC and CBD preparations to Spanish hospital pharmacies
• Leverages existing EU-GMP facility and prior 2020 AEMPS license for medicinal cannabis derivatives in Spain

Negative

• None.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Milestone reinforces Curaleaf's leadership in bringing pharmaceutical-grade cannabis products to emerging international markets

STAMFORD, Conn., July 13, 2026 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer cannabis products, today announced that the Spanish Agency of Medicines and Medical Devices ("AEMPS") has formally approved the registration of two standardized cannabis preparations (THC-dominant and CBD-dominant) developed by Curaleaf's Spanish manufacturing subsidiary. These registrations clear the regulatory pathway for the supply of preparations to hospital pharmacies, where they can be used in the production of magistral formulas pursuant to medical prescription. Based on the official registry numbering (CAN-1 and CAN-2), Curaleaf is the first company to register standardized cannabis preparations in Spain under the country's new regulatory framework, Royal Decree 903/2025.

Approved by Spain's Council of Ministers on October 7, 2025, Royal Decree 903/2025 establishes Spain's regulatory framework for the medicinal use of standardized cannabis preparations, setting out the requirements for their production, quality standards, and registration with AEMPS. It provides, for the first time, a clear national pathway for patients to access standardized cannabis preparations through the healthcare system. Curaleaf's registrations under this new framework mark one of the first steps in bringing that pathway to life.

The registrations build on Curaleaf's long-established presence in Spain, where the Company operates an EU-GMP certified manufacturing facility and R&D laboratory in Alicante. In May 2020, Curaleaf's EU-GMP laboratory, Medalchemy SL, secured the first-ever license granted by AEMPS to process medicinal cannabis derivatives for commercial distribution, an early milestone that laid the foundation for today's achievement.

'Spain, a country of nearly 50 million people, has always been central to Curaleaf's vision for Europe, and this registration is a defining moment for us," said Boris Jordan, CEO and Chairman of Curaleaf. "We were the first company to be licensed here in 2020, and we believe we are the first to register under this new framework today. This achievement reflects the strength of our team, our sustained investment in science, and our conviction that patients deserve access to standardized, high-quality cannabis medicines."

The standardized preparations are expected to become available to patients through hospital pharmacies in due course, in line with the requirements of the new framework. Curaleaf will continue to work alongside healthcare professionals and partners to support access as Spain's regulated system takes shape.

About Curaleaf Holdings 
Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf") is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select, Grassroots, Find, Dark Heart, and Anthem, provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is powered by a strong presence in all stages of the supply chain. Its unique distribution network throughout Europe, Canada and Australasia brings together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Toronto Stock Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com.

Forward Looking Statement
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans", "expects" or "proposed", "is expected", "intends", "anticipates", or "believes", or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward-looking statements and information concerning the expected availability of the Company's standardized cannabis preparations to patients through hospital pharmacies in Spain, the timing thereof, the anticipated implementation and rollout of Spain's regulatory framework for the medicinal use of standardized cannabis preparations under Royal Decree 903/2025, and the Company's ability to support patient access as that framework takes shape. The availability of these preparations is subject to the requirements of the new regulatory framework, the discretion of Spanish health authorities, and the pace at which the regulated system is implemented and may be delayed or may not occur as anticipated. There can be no assurance that any of these potential effects will be realized within the expected timeframe or at all, as implementation depends on regulatory action and other factors outside the Company's control. Such forward-looking statements and information reflect management's current beliefs and are based on assumptions made by and information currently available to the Company with respect to the matter described in this news release. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information about these assumptions and uncertainties is contained under "Risk Factors and Uncertainties" in the Company's latest annual information form filed on February 26, 2026, which is available under the Company's profile on SEDAR+ at www.sedarplus.ca, and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. The Toronto Stock Exchange has not reviewed, approved or disapproved the content of this news release.

Investor Contact:
Curaleaf Holdings, Inc.
Camilo Lyon, Chief Investment Officer
IR@curaleaf.com

Media Contact:
MATTIO Communications
MattioCuraleaf@Mattio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/curaleaf-first-to-secure-registration-for-standardized-cannabis-preparations-in-spain-302823474.html

SOURCE Curaleaf Holdings, Inc.

FAQ

What did Curaleaf (CURLF) announce about its cannabis registrations in Spain on July 13, 2026?

Curaleaf announced AEMPS approval for registering two standardized cannabis preparations in Spain. According to Curaleaf, the THC-dominant and CBD-dominant products can now be supplied to hospital pharmacies for magistral formulas under prescription, marking a key step in Spain’s new medicinal cannabis framework.

Why are Curaleaf's CAN-1 and CAN-2 registrations in Spain important for CURLF investors?

The CAN-1 and CAN-2 registrations make Curaleaf the first to register standardized cannabis preparations under Spain’s Royal Decree 903/2025. According to Curaleaf, this clears a national pathway to supply hospital pharmacies, potentially expanding access to its pharmaceutical-grade cannabis within Spain’s healthcare system.

How does Royal Decree 903/2025 affect Curaleaf's medicinal cannabis business in Spain (CURLF)?

Royal Decree 903/2025 sets Spain’s framework for medicinal use of standardized cannabis preparations. According to Curaleaf, it defines production, quality, and registration requirements and creates a clear national pathway for patients to access standardized preparations through the healthcare system, enabling Curaleaf’s newly registered products.

When will Curaleaf's standardized cannabis preparations be available to patients in Spain?

Curaleaf expects its standardized preparations to become available through hospital pharmacies in due course. According to Curaleaf, distribution timing will follow the requirements of Royal Decree 903/2025, as the regulated system and access pathways continue to take shape with healthcare professionals and partners.

What role does Curaleaf's EU-GMP facility in Alicante play in its Spain strategy for CURLF?

Curaleaf’s EU-GMP certified facility and R&D lab in Alicante underpin its Spanish operations. According to Curaleaf, the site and its Medalchemy SL lab, licensed by AEMPS since 2020, laid the foundation for securing the new standardized preparation registrations CAN-1 and CAN-2.

How does Curaleaf describe Spain's importance within its European cannabis strategy (CURLF)?

Curaleaf describes Spain, with nearly 50 million people, as central to its European vision. According to Curaleaf, being first licensed in 2020 and first to register standardized preparations under the new framework marks a defining moment for its medicinal cannabis strategy in the country.